PMID- 7555507
OWN - NLM
STAT- MEDLINE
DCOM- 19951121
LR  - 20221207
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 18
IP  - 6
DP  - 1995 Jun
TI  - Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density 
      lipoprotein subfractions to oxidation and on protein glycation in NIDDM.
PG  - 807-16
AB  - OBJECTIVE: To evaluate the effect of vitamin E supplementation on the 
      susceptibility of low-density lipoprotein (LDL) and LDL subfractions to oxidation 
      and on protein glycation in non-insulin-dependent diabetes mellitus (NIDDM). 
      RESEARCH DESIGN AND METHODS: Twenty-one men with NIDDM (HbA1c = 6-10%), ages 
      50-70, were randomly assigned to either 1,600 IU/day of vitamin E or placebo for 
      10 weeks after a 4-week placebo period. LDL and LDL subfractions were isolated 
      after 4 weeks of placebo and after 6 and 10 weeks of therapy. Susceptibility of 
      LDL to copper-mediated oxidation was measured by conjugated diene formation (lag 
      time) and formation of thiobarbituric acid-reactive substances (TBARS). Fasting 
      serum glucose, mean weekly blood glucose, HbA1c, and glycated plasma protein 
      concentrations were also determined at these time points. RESULTS: Vitamin E 
      content in plasma and LDL increased 4.0- and 3.7-fold, respectively, in the 
      vitamin E-treated group. Vitamin E decreased the susceptibility of LDL to 
      oxidation in comparison with placebo (lag time, 243 +/- 46 vs. 151 +/- 22 min, P 
      < 0.01; 3 h TBARS, 24 +/- 12 vs. 66 +/- 18 nmol malondialdehyde/mg LDL, P < 
      0.05). Vitamin E content also increased significantly in both buoyant and dense 
      LDL subfractions, and their oxidation was dramatically reduced. The lag time of 
      LDL oxidation correlated well with the content of vitamin E in both LDL and its 
      subfractions (r = 0.69-0.92). Glycemic indexes did not change significantly in 
      either group during the study. Protein glycation, including glycated hemoglobin, 
      glycated albumin, glycated total plasma proteins, and glycated LDL were unchanged 
      in the vitamin E group. CONCLUSIONS: Supplementation of vitamin E in NIDDM leads 
      to enrichment of LDL and LDL subfractions and reduced susceptibility to 
      oxidation. Despite a greater percentage increase in vitamin E content in small 
      dense LDL, it remained substantially more susceptible to oxidation than was 
      buoyant LDL. This suggests that dense, LDL may gain less protection against 
      oxidation from antioxidant supplementation than does larger, more buoyant LDL. In 
      contrast to previous reports, vitamin E supplementation did not reduce glycation 
      of intracellular or plasma proteins.
FAU - Reaven, P D
AU  - Reaven PD
AD  - Division of Endocrinology and Metabolism, University of California, San Diego, La 
      Jolla 92093-0682, USA.
FAU - Herold, D A
AU  - Herold DA
FAU - Barnett, J
AU  - Barnett J
FAU - Edelman, S
AU  - Edelman S
LA  - eng
GR  - HL-14197/HL/NHLBI NIH HHS/United States
GR  - MO1-RR00827/RR/NCRR NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Blood Glucose)
RN  - 0 (Blood Proteins)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Glycoproteins)
RN  - 0 (Hexosamines)
RN  - 0 (Insulin)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Serum Albumin)
RN  - 0 (Thiobarbituric Acid Reactive Substances)
RN  - 0 (Triglycerides)
RN  - 1406-18-4 (Vitamin E)
RN  - 4429-04-3 (Fructosamine)
RN  - 789U1901C5 (Copper)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - 0 (Glycated Serum Proteins)
RN  - 0 (Glycated Serum Albumin)
SB  - IM
MH  - Aged
MH  - Blood Glucose/metabolism
MH  - Blood Proteins/analysis
MH  - Cholesterol/blood
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Copper
MH  - Diabetes Mellitus, Type 2/*blood/*drug therapy
MH  - Fructosamine
MH  - Glycated Hemoglobin/analysis
MH  - Glycation End Products, Advanced
MH  - *Glycoproteins
MH  - Glycosylation
MH  - Hexosamines/analysis
MH  - Homeostasis
MH  - Humans
MH  - Insulin/blood
MH  - Lipoproteins, LDL/*blood/drug effects
MH  - Male
MH  - Middle Aged
MH  - Oxidation-Reduction
MH  - Serum Albumin/analysis
MH  - Thiobarbituric Acid Reactive Substances
MH  - Time Factors
MH  - Triglycerides/blood
MH  - Vitamin E/blood/*therapeutic use
MH  - Glycated Serum Proteins
MH  - Glycated Serum Albumin
EDAT- 1995/06/01 00:00
MHDA- 1995/06/01 00:01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 1995/06/01 00:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
AID - 10.2337/diacare.18.6.807 [doi]
PST - ppublish
SO  - Diabetes Care. 1995 Jun;18(6):807-16. doi: 10.2337/diacare.18.6.807.